Promising new molecular targeted therapies in head and neck cancer

Drugs

Volumn 73, Issue 4, 2013, Pages 315-325

  Dorsey, Kelly ^a   Agulnik, Mark ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; FLUOROURACIL; FORETINIB; GEFITINIB; LAPATINIB; METHOTREXATE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VANDETANIB; ZALUTUMUMAB;

ACNE; ADD ON THERAPY; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BLEEDING; BREAST METASTASIS; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CHEMORADIOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INDUCTION CHEMOTHERAPY; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIGAND BINDING; LUNG NON SMALL CELL CANCER; METASTASIS; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN DEPHOSPHORYLATION; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TUMOR INVASION; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

HUMAN PAPILLOMAVIRUS;

EID: 84878846850     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0025-3     Document Type: Article

References (82)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Westra WH. The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol. 2009;3(1):78-81.
3. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31:744-54.
4. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110:1429-35.
5. Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol. 2003;39:222-31.
6. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24-35.
7. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261-9.
8. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol. 2002;13:995-1006.
9. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114:806-16.
10. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2644-52.
11. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004;22:1743-52.
12. Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol. 2012;29(4):2481-91.
13. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003;284:99-110.
14. Hynes NE, Horsch K, Olayioye MA, Badache A. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer. 2001;8:151-9.
15. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control. 2007;14:295-304.
16. Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 2002;110:775-87.
17. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002;110:669-72.
18. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-37.
19. Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res. 2003;1:801-9.
20. Masuda M, Toh S, Koike K, et al. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res. 2002;93:329-39.
21. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501.
22. Ellerbroek SM, Halbleib JM, Benavidez M, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 2001;61:1855-61.
23. Shtiegman K, Yarden Y. The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin Cancer Biol. 2003;13:29-40.
24. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7(Suppl. 4):31-9.
25. Cruz JJ, Ocana A, Del Barco E, Pandiella A. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol. 2007;18:421-30.
26. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl. 4):S9-15.
27. Zimmermann M, Zouhair A, Azria D, Ozsahin M. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 2006;1:11.
28. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984;44:1002-7.
29. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-78.
30. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-8.
31. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24:1072-8.
32. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC) [abstract no. 5500]. J Clin Oncol. 2011;29(Suppl.).
33. Lefebvre J, Pointreau Y, Rolland F, et al. Sequential chemoradiotherapy (SRCT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study [abstract no. 5501]. J Clin Oncol. 2011;29(Suppl.).
34. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646-54.
35. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-27.
36. Vermorken JB, Peyrade F, Krauss J, et al. Cilengitide with cetuximab, cisplatin, and 5-FU in R/M SCCHN: the ADVANTAGE phase II trial [abstract no. 5516]. J Clin Oncol. 2012;30(Suppl.).
37. Guigay J, Fayette J, Dillies AF, et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Final results of phase II trial GORTEC 2008-03 [abstract no. 5505]. J Clin Oncol. 2012;30(Suppl.).
38. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-7.
39. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568-77.
40. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5578-87.
41. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17-23.
42. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004;58:984-90.
43. Giralt J, Fortin A, Mesia R, et al. A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients with unresected, locally advanced squamous cell carcinoma of the head and neck [abstract no. 5502]. J Clin Oncol. 2012;30(Suppl.).
44. Vermorken JB, Stohlmacher J, Davidenko I, et al. Primary efficacy and safety results of SPECTRUM, a phase 3 trial in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without panitumumab [abstract no. LBA26]. Ann Oncol 2010;21(Suppl. 8).
45. Stoehlmacher-Williams J, Villanueva C, Foa P, et al. Safety and efficacy of panitumumab in HPV-positive and HPV-negative recurrent/metastatic squamous cell carcinoma of the head and neck: analysis of the global phase III SPECTRUM trial [abstract no. 5504]. J Clin Oncol. 2012;30(Suppl.).
46. Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12:333-43.
47. Ramakrishnan, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs. 2009;1(1):41-8.
48. Babu KG, Viswanath L, Reddy BK, et al. An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four-year survival results from a phase IIb study [abstract no. 5530]. J Clin Oncol. 2010;28(Suppl.).
49. Rodriguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010;9(5):343-9.
50. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21:1980-7.
51. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected; published erratum appears in J Clin Oncol 2009;27(20):3410]. J Clin Oncol. 2009;27(11):1864-71.
52. Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebo controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern cooperative oncology group (ECOG) [abstract no. 6011]. J Clin Oncol. 2009;27(Suppl):15.
53. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85.
54. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol. 2007;25:2178-83.
55. Kim ES, Kies, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J Clin Oncol 2007 ASCO Ann Meet Proc Part I. 2007;25:6013.
56. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol. 2007;25:4057-65.
57. Harrington KJ, Berrier A, Robinson M, et al. Phase II study of oral lapatinib, a dual tyrosine kinase inhibitor, combined with CRT in patients with locally advanced, unresected SCCHN [abstract no. 5505]. J Clin Oncol. 2010;28:15 Suppl.
58. Del Campo JM, Hitt R, Sebastian P, et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy naive patients with locally advance SCCHN. Br J Cancer. 2011;105:618-27.
59. Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent /metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN) [abstract no. 5568]. J Clin Oncol. 2006;24:18 Suppl.
60. Seiwert TY, Fayette J, Del Campo JM, et al. Updated results of a randomized, open-label phase II study exploring BIBW 2992 versus cetuximab in patients with platinum refractory metastatic/recurrent head and neck cancer (SCCHN) [abstract no. 1010PD]. Ann Oncol. 2010;21(Suppl):8.
61. Siu LL, Hotte SJ, Laurie SA, et al. Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) [abstract no. 5561]. J Clin Oncol. 2011;29 Suppl.
62. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6.
63. Zhong H, Bowen JP. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem. 2007;7:1379-93.
64. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-6.
65. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11:1434-40.
66. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol. 2005;18:485-94.
67. Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29:1140-5.
68. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009;10:247-57.
69. Argiris A, Kotsakis AP, Kim S, et al. Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck: final results [abstract no. 5564]. J Clin Oncol. 2011;29:Suppl.
70. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol. 2010;28:3330-5.
71. Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007;25:3766-73.
72. Blumenschein GR, Glisson BS, Lu C, et al. Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent SCCHN [abstract no. 5592]. J Clin Oncol. 2012;30:Suppl.
73. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010;16:3507-16.
74. Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G Jr. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Investig New Drugs. Epub 24 Aug 2012.
75. Bähr C, Groner B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors. 2005;23(1):1-14.
76. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57:1050-93.
77. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res. 2007;13:4291-9.
78. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505-18.
79. Mitsiades CS, Mitsiades N. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther. 2005;5:487-99.
80. Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer. 2007;96 suppl.:R2-6.
81. Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S, Moxhon A, Duprez T, Guigay J. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 2010;28(1):21-8.
82. Choong NW, Kozloff M, Taber D, Hu HS, Wade J 3rd, Ivy P, Karrison TG, Dekker A, Vokes EE, Cohen EE. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Investig New Drugs. 2010;28(5):677-83.